Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Moderna Inc., consolidated balance sheet: assets

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash and cash equivalents 2,907 3,205 6,848 2,624 236
Investments 5,697 6,697 3,879 1,984 867
Accounts receivable, net 892 1,385 3,175 1,391 5
Inventory 202 949 1,441 47
Prepaid services 182 216 126 16 8
Down payments to manufacturing vendors 100 229 118 217
Down payments for materials and supplies 68 219 287
Collaboration receivable 61 11
Interest receivable 59 61 27
Value added tax receivable 50 140 70
Income tax receivable 19 10
Tenant improvement allowance receivable 42 51 10 4
Prepaid income taxes 187 23
Convertible note receivable 36
Other current assets 88 44 26 11 8
Prepaid expenses and other current assets 627 1,195 728 253 20
Current assets 10,325 13,431 16,071 6,298 1,129
Investments, non-current 4,677 8,318 6,843 639 160
Property, plant and equipment, net 1,945 2,018 1,241 297 201
Right-of-use assets, operating leases 713 121 142 90 86
Deferred tax assets 81 982 326
Down payments and prepayments, non-current 342
Inventory, non-current 170 910
Equity investments 66 42
Goodwill 52
Finite-lived intangible asset 44
Restricted cash 4 12
Other 7 24 46 13 13
Other non-current assets 685 988 46 13 13
Non-current assets 8,101 12,427 8,598 1,039 461
Total assets 18,426 25,858 24,669 7,337 1,589

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Moderna Inc. current assets decreased from 2021 to 2022 and from 2022 to 2023.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Moderna Inc. property, plant and equipment, net increased from 2021 to 2022 but then slightly decreased from 2022 to 2023.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Moderna Inc. non-current assets increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Moderna Inc. total assets increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Moderna Inc. cash and cash equivalents decreased from 2021 to 2022 and from 2022 to 2023.
Investments Amount of investment in marketable security, classified as current. Moderna Inc. investments increased from 2021 to 2022 but then slightly decreased from 2022 to 2023.
Accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Moderna Inc. accounts receivable, net decreased from 2021 to 2022 and from 2022 to 2023.
Inventory Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Moderna Inc. inventory decreased from 2021 to 2022 and from 2022 to 2023.